The delayed rejection of tumors formed from the administration of tumor cells mixed with killed corynebacterium parvum

Therapeutic application of various immunostimulators on the L2C guinea-pig leukemia

“…Theoretically, one would have assumed that the systemic administration of C. parvum would have proved more advantageous in promoting an antileukemic effect than a s.c. inoculation. There is, however, considerable evidence to indicate that the s.c. injection of C. parvum is capable of producing specific systemic immunity in both solid and blood-borne tumors (Milas, 1973;Likhite and Halpern, 1973;Milas et al, 1974;Scott, 1974). Likhite and Halpern (1974) indicated that a maximal response could be obtained following the injection of C. parvum either directly into the tumor mass or as close to it as possible.…”

“…The dose, route, and frequency of administration of these stimulators has been determined both prophylactically and therapeutically in order to establish what regimen of treatment is needed to produce maximal suppression of tumor growth (Woodruff et al, 1976;Scott and Bomford, 1976;Smith and Scott, 1972;Halpern et al, 1973;Mohr et al, 1975;Pearson et al, 1973;DiLuzio, 1975;Chirigos et al, 1973;Milas, 1973). However, relatively little work has appeared in the literature concerning the therapeutic application of immunopotentiators in animal systems expressing tumors of hematopoietic origin (i.e., leukemias) (Math~ et al, 1973a(Math~ et al, , b, 1974Likhite and Halpern, 1973;Pearson et al, 1972). Since few leukemia models exist, heavy emphasis has been placed on the use of the L1210 (Mathe et al, 1969a(Mathe et al, ,b, 1973a(Mathe et al, , 1974Mohr et al, 1976), LSTRA (Smith and Scott, 1972;Pearson et al, 1972Pearson et al, , 1973, MCAs-10 (Pearson et al, 1974;Chirigos et al, 1975), and AKR (Ebbesen, 1974;Pendergrast et al, 1975;Math6 et al, 1973b) leukemia systems in mouse, and the Shay chloroleukemia model in rat (DiLuzio et al, 1976;DiLuzio, 1975;Likhite and Halpern, 1973).…”

“…However, relatively little work has appeared in the literature concerning the therapeutic application of immunopotentiators in animal systems expressing tumors of hematopoietic origin (i.e., leukemias) (Math~ et al, 1973a(Math~ et al, , b, 1974Likhite and Halpern, 1973;Pearson et al, 1972). Since few leukemia models exist, heavy emphasis has been placed on the use of the L1210 (Mathe et al, 1969a(Mathe et al, ,b, 1973a(Mathe et al, , 1974Mohr et al, 1976), LSTRA (Smith and Scott, 1972;Pearson et al, 1972Pearson et al, , 1973, MCAs-10 (Pearson et al, 1974;Chirigos et al, 1975), and AKR (Ebbesen, 1974;Pendergrast et al, 1975;Math6 et al, 1973b) leukemia systems in mouse, and the Shay chloroleukemia model in rat (DiLuzio et al, 1976;DiLuzio, 1975;Likhite and Halpern, 1973). Additional experimental model systems to study the application of active immunotherapy in leukemic animals are therefore highly desirable.…”

Rejection of tumor metastases in Fischer 344 rats following the administration of killed Corynebacterium parvum

“…Preparations of killed Corynebacterium parvum vaccine have also been observed to inhibit tumor growth from grafts of syngeneic tumor cells in experimental animals (Halpern et al, 1966;Woodruff and Boak, 1966). Subsequent studies have revealed that subcutaneous (SC) transplantation of tumor cells mixed with killed C. parvum resulted in a delayed rejection of the tumors formed in all recipients inoculated with tumor cells admixed with killed C. parvum (Likhite and Halpern, 1973). In addition, immediate rejection of growing SC tumors has been observed following a single intratumor infiltration of killed C. parvum (Likhite and Halpern, 1974).…”

Treatment of transplanted rat tumours with double-stranded RNA(BRL 5907). II. Treatment of pleural and peritoneal growths

“…For example, with Corynebacterium parvum, growth of carcinomata in the mouse (Likhite and Halpern, 1973) and rat sarcomata (Pimm and Hopper,1 975a) is restricted when cells are injected in admixture with killed organisms, and intralesional injections may lead to regression of a transplanted hamster melanoma (Paslin, Dimitrov and Heaton, 1974). In addition, growth of syngeneically transplanted rat (Baldwin and Pimm, 1971) and mouse (Bartlett, Zbar and Rapp, 1972) sarcomata is suppressed when tumour cells are injected in admixture with Bacillus Calmette-C(terin (BCG) organisms.…”